Physician profile
Gary M Davidson
NPI 1609872993
$1,625.63
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $336.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $220.62 | 2019-2020 | |
| Lilly USA, LLC | $186.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $129.83 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $105.11 | 2019-2020 | |
| Allergan, INC. | $84.15 | 2019-2020 | |
| Abbvie INC. | $82.08 | 2019-2020 | |
| Amgen INC. | $81.59 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $73.45 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $72.88 | 2019-2020 | |
| Amarin Pharma, INC. | $69.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $69.12 | 2019-2020 | |
| Astellas Pharma US INC | $49.46 | 2019 | |
| Merck Sharp & Dohme LLC | $45.44 | 2019 | |
| Abbott Laboratories | $41.86 | 2019 | |
| Glaxosmithkline, LLC. | $32.64 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $32.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.55 | 2019 | |
| Corcept Therapeutics | $28.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.88 | 2019 | |
| Pfizer INC. | $23.14 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.27 | 2019 | |
| Boston Scientific Corporation | $18.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.32 | 2019 | |
| Sanofi Pasteur INC. | $16.92 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.29 | 2019 | |
| Horizon Therapeutics Plc | $15.50 | 2019 | |
| Genentech USA, INC. | $14.52 | 2019 | |
| Hikma Pharmaceuticals USA | $13.10 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.66 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.